UroGen Pharma Ltd(URGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.99 | Insider Own | 15.08% | Shs Outstand | 48.9M | Perf Week | -4.91% |
| Market Cap | 2.06B | Forward P/E | 16.8 | EPS next Y | 1223.7% | Insider Trans | -1.32% | Shs Float | 41.5M | Perf Month | -10.34% |
| Enterprise Value | 2.15B | PEG | - | EPS next Q | 0.1 | Inst Own | 80.62% | Short Float | 12.34% | Perf Quarter | 50.86% |
| Income | -0.10B | P/S | 10.94 | EPS this Y | 92.99% | Inst Trans | -1.34% | Short Ratio | 6.25 | Perf Half Y | 124.2% |
| Sales | 0.19B | P/B | - | EPS next 5Y | - | ROA | -42.33% | Short Interest | 5.12M | Perf YTD | 80.36% |
| Book/sh | -2.71 | P/C | 18.89 | EPS past 3/5Y | 12.81% 11.57% | ROE | - | 52W High | -16.87% ($50.81) | Perf Year | 121.04% |
| Cash/sh | 2.24 | P/FCF | - | Sales past 3/5Y | 19.49% 56.22% | ROIC | -158.4% | 52W Low | 166.33% ($15.86) | Perf 3Y | 154.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.9% | Gross Margin | 90.85% | Volatility(W/M) | 5.38% 4.4% | Perf 5Y | 164.33% |
| Dividend TTM | - | EV/Sales | 11.4 | Sales Y/Y TTM | 100.27% | Oper. Margin | -35.32% | ATR (14) | 2.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.41 | EPS Q/Q | 72.78% | Profit Margin | -51.73% | RSI (14) | 42.31 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.8 | Sales Q/Q | 199.22% | SMA20 | -7.86% ($45.84) | Beta | 1.57 | Target Price | $58.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/5 | SMA50 | -2.04% ($43.12) | Rel Volume | 0.84 | Prev Close | $45 |
| Employees | 291 | LT Debt/Eq | - | EPS/Sales Surpr. | -5.66% 14.02% | SMA200 | 47.91% ($28.56) | Avg Volume(3M) | 0.82M | Price | $42.24 |
| IPO | 2017/5/4 | Option/Short | Yes/Yes | Trades | 7826 | Volume | 686,322 | Change | -6.13% |
Company
URGN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 UroGen Pharma is a US-listed biotech company targeting urological and urothelial cancers. Leveraging its proprietary RTGel drug delivery technology, the company develops and commercializes non-surgical treatments for low-grade cancers of the bladder and upper urinary tract. Expanding launches of approved products and advancing its late-stage clinical pipeline serve as its key growth drivers.
Over the past 1 year, on the higher side
17% below its 1-year high.
URGN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +93.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +154.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 80.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IZRL 0.02%
CANC 0.01%
IWC 0.00%
ACSG 0.00%
FSEG 0.00%It ranks #4 in the industry
Based on market cap of $2B.
URGN $2B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is URGN?
URGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of URGN?
The market cap of URGN is approximately $2.1B, ranking 2,072 within its sector.
What is the 52-week high and low for URGN?
URGN has recorded a 52-week high of $50.81 and a low of $15.86.
